BioSpace News Archive

Exogenesis Corporation today announced that a series of challenge tests for the Exogenesis Surgical Mask (ESM) achieved its primary endpoints of trapping and deactivating COVID-19 viral particles in simulated real-world exposures. The Exogenesis Surgical Mask (ESM) is designed to provide protective nose and mouth covering for h

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its August 2020 SARS-CoV-2 Testing Survey for clinical laboratories.

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance exchange, announced today that the company plans to release third quarter 2020 financial results on October 22, 2020.

American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s presentation will highlight the company’s technology, including AGT103-T, a therapeutic intended to cure HIV, which is scheduled to begin Phase 1 clinical trials this month. Specifics

Patients who recovered from COVID-19 at St. Luke’s University Health Network have donated their antibody-rich blood to medical science in hopes of helping to find an effective treatment or cure to the novel coronavirus that has killed nearly 200,000 Americans.

Real-Time Analyzers, Inc., (RTA) developer of chemical and biological agent analyzers for the U.S. military, today announced that the company has developed a simple-to-use saliva-based COVID-19 test kit.

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19 Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolution

Application of ImmTOR™ plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN ) Selecta’s IgA nephropathy program builds upon SEL-212 , which has demonstrated ImmTOR™ e ffective at tolerizing a highly immunogenic therapeutic enzyme Investigational New Drug (IND) application expected in Q4 2021 WATERTOWN, Mass., and BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences

GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial results for the quarter ended September 30, 2020. Third Quarter 2020 Highlights Placed net 70 ePlex ® analyzers, finishing the quarter with a global installed base of more than 720 ePlex analyzers, an increase of 47% versus the third quarter of 2019 Total revenue expected to

RP2 Panel at a Glance GenMark’s ePlex ® Respiratory Pathogen Panel 2 (RP2 Panel) has received Emergency Use Authorization from the FDA. The RP2 Panel provides results in less than two hours for more than 20 viruses and bacteria that cause common respiratory infections with similar symptoms, including COVID-19, flu, bronchitis and the common cold. The rapid, multiplex molecular testing offered by the RP2 Panel will be vital in preparing for the fall and winter, when COVID-19 will be cir